Menu
Back to User profile » Dr Kyoung Soo Lim
Papers published by Dr Kyoung Soo Lim:
A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers
Shin W, Lim KS, Kim MK, Kim HS, Hong J, Jhee S, Kim J, Yoo S, Chung YT, Lee JM, Cho DY
Drug Design, Development and Therapy 2019, 13:1011-1022
Published Date: 29 March 2019
Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers
Jang K, Kim M, Oh J, Lee S, Cho JY, Yu KS, Choi TK, Lee SH, Lim KS
Drug Design, Development and Therapy 2017, 11:705-711
Published Date: 9 March 2017
Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers
Choi YJ, Han HK, Shin D, Lim KS, Yu KS
Drug Design, Development and Therapy 2015, 9:4127-4135
Published Date: 31 July 2015
A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles
Chung H, Lee H, Han H, An H, Lim KS, Lee YJ, Cho JY, Yoon SH, Jang IJ, Yu KS
Drug Design, Development and Therapy 2015, 9:2609-2616
Published Date: 13 May 2015
Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects
Hong T, Han S, Lee J, Jeon S, Park GJ, Park WS, Lim KS, Chung JY, Yu KS, Yim DS
Drug Design, Development and Therapy 2015, 9:1233-1245
Published Date: 26 February 2015
A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects
Park SI, Lee H, Oh J, Lim KS, Jang IJ, Kim JA, Jung JH, Yu KS
Drug Design, Development and Therapy 2015, 9:729-736
Published Date: 4 February 2015
Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers
Lee J, Lee H, Jang K, Lim KS, Shin D, Yu KS
Drug Design, Development and Therapy 2014, 8:1781-1788
Published Date: 8 October 2014
Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study
Kim S, Lee J, Shin D, Lim KS, Kim YS, Jang IJ, Yu KS
Drug Design, Development and Therapy 2014, 8:1723-1731
Published Date: 6 October 2014
Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
Gu N, Park MK, Kim TE, Bahng MY, Lim KS, Cho SH, Yoon SH, Cho JY, Jang IJ, Yu KS
Drug Design, Development and Therapy 2014, 8:1709-1721
Published Date: 6 October 2014
Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects
Cha YJ, Lim KS, Park MK, Schneider S, Bray B, Kang MC, Chung JY, Yoon SH, Cho JY, Yu KS
Drug Design, Development and Therapy 2014, 8:1613-1619
Published Date: 26 September 2014
Predictive performance of gentamicin dosing nomograms
Lee J, Yoon S, Shin D, Han H, An H, Lee J, Lim KS, Yu KS, Lee H
Drug Design, Development and Therapy 2014, 8:1097-1106
Published Date: 16 August 2014